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Albendazole-lipid nanocapsules: optimization, characterization and chemoprophylactic 1 
efficacy in mice infected with Echinococcus granulosus 2 
ABSTRACT 3 
Cystic echinococcosis (CE), which is caused by during the metacestode larval stage of Echinococcus 4 
granulosus, is a life-threatening disease and is very difficult to treat. At present, the FDA-approved 5 
antihelmintic drugs are mebendazole (MBZ), albendazole (ABZ) and its principal metabolite ABZ 6 
sulfoxide (ABZSO), but as these have with a therapeutic efficacy over 50%, underlining the need for 7 
new drug delivery systems. The aim of this work was the optimization and characterization of to 8 
optimised and fully characterizes the previously developed ABZ lipid nanocapsules (ABZ-LNCs) 9 
previously developed and evaluate their efficacy in mice infected with E. granulosus the murine 10 
model of CE. LNCs were prepared by the phase inversion technique and characterized in terms of 11 
size, surface charge, drug loading, and i  vitro stability followed by an in vivo proof-of-concept 12 
performed in using a CE murine model murine model infected with E. granulosus. Stable particles 13 
dispersions with a narrow size distribution and high efficiency of encapsulation (≥90%) were 14 
obtained. ABZ-LNCs showed a greater chemoprophylactic efficacy than ABZ suspension 15 
administered by the oral route since as 4 out of the 10 ABZ-LNCs treated mice did not develop any 16 
cysts, whereas the infection progressed in all mice from the ABZ suspension group. Regarding the 17 
ultrastructural studies of cysts, mice treated with ABZ-LNCs or ABZ suspension revealed changes in 18 
the germinal layer. However, the extent of the damage ppeared to be greater after ABZ-LNCs 19 
administration compared to the suspension treatment. These results suggested that ABZ-LNCs are 20 
could be a promising novel candidate for ABZ delivery to treat CE. 21 
 22 
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1. INTRODUCTION 27 
Cystic echinococcosis (CE), a zoonosis caused by the larval stage of Echinococcus 28 
granulosus, is characterized by the long-term growth of cysts in humans and mammalian 29 
intermediate hosts (McManus et al., 2012). This is  a chronic and complex parasitic infection is a 30 
chronic, complex, and still neglected disease (Brunetti and Junghanss, 2009). Currently, four 31 
treatment approaches are used in use: surgery, PAIR (puncture, aspiration, injection of 32 
protoscolicidal agent and reaspiration), chemotherapy with benzimidazoles (BZ), and watching and 33 
waiting for the appearance of inactive, clinically silent cysts (Stojkovic et al. 2009). Albendazole 34 
(ABZ) and mebendazole (MBZ) are the BZ commonly indicated for inoperable patients with 35 
multiple cysts in two or more organs and, also for the prevention of secondary echinococcosis after 36 
surgery (Pawłowski et al., 2001). According to WHO recommendations, ABZ should be 37 
administered in daily doses of 10-15 mg/kg of body weight taken in two divided doses post-38 
prandially for 3-6 months (WHO Informal Working Group on Echinococcosis, 2001). Nevertheless, 39 
approximately only one-third of patient’s experiencs complete remission or cure, with and 30-50% 40 
of treated patients developing some evidence of a therapeutic response (Moro and Schantz, 2009). 41 
Despite this questionable efficacy, ABZ remains thebest treatment option for inoperable human 42 
cases, and is the drug of choice for perioperative prophylaxis due to the lack of alternative drugs 43 
against hydatid cysts.  44 
Regarding the oral route, the low aqueous solubility coupled to with the slow dissolution rate 45 
of ABZ generally leads to a poor and erratic absorpti n from the gastro-intestinal tract. (Alanazi et 46 
al. 2007; Martinez-Marcos et al. 2016; Castro et al. 2010). Thus, several options are currently being 47 
explored in order to overcome these drawbacks improve ABZ solubility. One A viable strategy is the 48 
choice of a dissolution medium that allow the ionization of this molecule in acidic medium since the 49 
drug is basic in nature but this solubility enhancement is not enough for preparing formulations 50 















surfactants, such as polysorbate and bile salts (del Estal et al. 1994; Torrado et al. 1996). However, 52 
the detergents properties of these formulations are associated with irritation of the digestive mucosa. 53 
Similarly, the complexation with cyclodextrins (Pradines et al., 2014) or co-grinding ABZ with 54 
various excipients (Pluronic 188®, lactose monohydrate, corn starch, polyvinylpyrrolid ne, 55 
hydroxypropylmethyl cellulose and sodium lauryl sulphate) using  jet-milling and solid dispersion 56 
techniques (Castro et al., 2012; Vogt et al., 2008) were also tested without any clear benefits being 57 
found.  58 
In relation With respect to CE, it is important to highlight that the success of the post-surgical 59 
chemoprophylactic treatment is based upon the capacity of ABZ to operate on inhibit the 60 
protoscoleces in order to avoid their establishment and the development to of cysts. Therefore, the 61 
development of novel formulations that  facilitate th  controlled able to control the drug release of 62 
the drug to the target site is still now a an ongoi challenge. Nanotechnology-based delivery 63 
systems have emerged as promising alternatives to for improving the therapeutic efficiency of ABZ 64 
based on its by selective targeting and a tunable delivery rate, although their n vivo effectiveness has 65 
was not been extensively studied (Kang et al., 2015; Liu et al., 2013; Mukherjee and Plakogiannis, 66 
2010; Press, 2010). Among these, lipid nanoparticles w re developed according to using a phase 67 
inversion process that leads follows the formation of an oil/water microemulsion containing an oily 68 
fatty phase, surrounded by a rigid tensioactive shell (H urtault et al. 2002). These particles are were 69 
synthesized without the use of an organic solvent with a narrow size distribution which could be 70 
adjusted through precise modifications in pharmaceuti ally acceptable excipient proportions 71 
(Hirsjärvi et al., 2013; Huynh et al., 2009). Previously, it has been was shown that orally-72 
administered LNCs can permeate through the mucus, increase drug absorption by the epithelial 73 
tissue, and finally, increase drug bioavailability (Roger et al., 2009a, 2009b, 2017). Concerning the 74 
CE, ABZ loaded LNCs were reported to improved the bioavaibility of ABZ in the plasma and cysts 75 















(Pensel et al., 2015). Taking into account these above findings considerations, this study was 77 
conducted in order to optimized ABZ loaded LNCs and to characterized them in terms of size, 78 
surface potential, encapsulation efficiency, and i  vitro drug stability. The chemoprophylactic 79 
efficacy of this formulation was then evaluated in mice infected with E. granulosus. 80 
2. MATERIALS AND METHODS 81 
2.1. Materials 82 
ABZ powder was purchased to from Parafarm (Buenos Aires, Argentina) and Captex 8000® 83 
(tricaprylin) was supplied by Abitec Corp. (Colombus, Ohio, USA). The lipophilic Labrafac® WL 84 
1349 (caprylic-capric acid triglycerides; European Pharmacopeia, IVth, 2002) and Transcutol HP® 85 
(diethylene glycol monoethyl ether) were kindly provided by Gattefossé S.A.S (Saint-Priest, France). 86 
Lipoid® S75-3 (soybean lecithin at with 70% of phosphatidylcho ine and 10% of 87 
phosphatidylethanolamine) and Koliphor® HS-15 (mixture of free polyethylene glycol 660 and 88 
polyethylene glycol 660 hydroxystearate) were gifts from Lipoid Gmbh (Ludwigshafen, Germany) 89 
and BASF (Ludwigshafen, Germany), respectively. Due to the complex composition of each 90 
product, the brand names will be used from here on in the following text. NaCl was purchased from 91 
the Cicarelli lab (Buenos Aires, Argentina), and oleic acid (OA), monobasic ammonium phosphate, 92 
polisorbate 80 (Tween 80®) and Carboxymethilcellulose (CMC) were purchased from Sintorgan 93 
(Buenos Aires, Argentina). Porcine pepsin and pancreatin (reagent grade) enzymes were American 94 
Chemical Society (ACS) and were bought from Sigma (St. Louis, MO, USA). Purified water was 95 
obtained from MilliQ System (Biopore, Buenos Aires, Argentina). All other chemical reagents were 96 
of HPLC-grade and acquired from Sintorgan, Argentina. 97 
 98 
2.2. LNCs formulations 99 
The LNCs were prepared according to a the process dcribed by Heurtault et al., 2002 100 















oily matrix (Labrafac®, Captex®8000 or a mix of them) was added, and the mixture was heated at 80 102 
ºC for 5 min. After cooling, Lipoid® S75-3 (0.075g), Kolliphor ®HS-15 (0.846g), NaCl (0.089g) and 103 
water (2.96 g) were added and homogenized under magnetic stirring. Three cycles of progressive 104 
heating and cooling between 60-85°C were carried out and which was followed by an irreversible 105 
shock induced by dilution with through the addition of deionised water (12.5 g) added to the mixture 106 
at 75 °C. Afterwards, a slow magnetic stirring was applied to the suspension of LNCs for 5 min at 107 
room temperature. The final concentration of ABZ was 0.29 mg/g. 108 
2.3. Particle size and zeta potential (ZP) measurements 109 
The particle size, based on a volume distribution values, (D90), the polydispersity index (PI), 110 
and zeta (ζ) potential were determined by dynamic light scattering (DLS) on a DelsaNano-C 111 
instrument (Beckman Coulter, Osaka, Japan) fitted with a 488-nm laser beam at a fixed angle (90°) 112 
at 25°C with using DelsaNano 2.20 (Beckman Coulter, Osaka, Japan) instrument software. All 113 
measurements were performed in triplicate and nanocapsules were diluted 1:20 (v/v) in with 114 
deionised water. 115 
 116 
2.4. Scanning electron microscopy (SEM)  117 
The morphological structures of LNCs were investigated using a the scanning electron 118 
microscope LEO Model EVO 40XVP (Göttingen, Germany). The nanoparticle suspensions were 119 
diluted (1:400) in distilled water and fixed on a brass stub using a double-sided aluminium tape. To 120 
improve the conductivity, samples were gold-coated un er vacuum by employing a sputter coater 121 
PELCO Model 3.  122 
 123 
2.5. LNCs drug payload and encapsulation efficiency  124 
After formulation, LNCs were filtered using a Minisart® 0.2 µm filter (Vivascience AG, 125 
Hanovre, Germany) in order to eliminate not unencapsulated ABZ crystals. and samples were 126 















was measured by liquid chromatography (HPLC) in triplicate experiments. A Waters HPLC 1525 128 
pump with a Waters 717 plus autosampler was used, and 20 µl aliquot of the filtrate was injected into 129 
a reversed phase C18 column (250×4.6mm i.d., 5µm particle size, Luna, Phenomenex®). The oven 130 
temperature was maintained at 40 °C using a Waters column heater 1500 series. The assay analysis 131 
was performed with 0.01M monobasic ammonium phosphate and methanol (40:60) as mobile phase, 132 
at a flow rate of 1.3 ml/min. Eluting fractions were revealed with a PDA UV detector 2296 (lambda 133 
295 nm). The mean ± SD drug content was calculated (mg of ABZ/g LNCs dispersion). and the 134 
efficiency of encapsulation (EE%) was determined by dividing the experimental by the theoretical 135 
drug loading.  136 
 137 
2.6. Storage stability studies 138 
The stability of ABZ-loaded LNCs dispersion was evaluated after storage at 4-8 ºC for 2 139 
months. and the particle size distribution and drug loading were determined as previously described 140 
above. 141 
 142 
2.7. Stability of the nanocapsules in simulated gastrointestinal fluids 143 
As these nanostructures were developed as carriers int nded for oral administration of ABZ, 144 
thus we evaluated their stability in the gastrointestinal fluids. An aliquot (50 µl) of ABZ-LNCs (0.29 145 
mg/g) were was placed in a glass tube in triplicate and incubated at 37 °C under moderate stirring 146 
(100 rpm), either in 2.95 ml of simulated gastric medium (USP XXVII, pH=1.2, pepsin 0.32% w/v) 147 
and or in simulated intestinal medium (USP XXVII, pH=6.8, pancreatin 1% w/v). Samples from 148 
each tube were collected at a predetermined incubation time and centrifuged for 5 min at 5000 g in 149 
order to precipitate the enzymes. Then, the mean particle size of the remaining non-aggregated 150 
nanocapsules was determined by DLS. In order to check the ABZ loading, the samples were filtered 151 















precipitated ABZ, and the drug payload was determined by HPLC in triplicate as it was described in 153 
section 2.5. 154 
2.8. Animal studies 155 
Animal procedures and management protocols were approved by the Institutional Animal 156 
Care and Use Committee (RD RD 148/15) of the Faculty of Exact and Natural Sciences, National 157 
University of Mar del Plata (Mar del Plata, Argentina), and carried out in accordance with the 2011 158 
revised form of The Guide for the Care and Use of Laboratory Animals published by the U.S. 159 
National Institutes of Health. Any unnecessary animal suffering was avoided throughout the study. 160 
Female CF-1 mice (n=40; body weight 25±5g) were infected by intraperitoneal inoculation with 161 
1500 E. granulosus protoscoleces/animal, suspended in 0.5 ml of medium 199 (Gibco, Thermo 162 
Fisher Scientific, Argentina). The animals were housed in a temperature-controlled (22 ± 1 °C), 163 
light-cycled (12-hour light/dark cycle) room. Food and water were given ad libitum. 164 
 165 
2.8.1. Protoscoleces collection 166 
Protoscoleces of E. granulosus were collected aseptically from liver and lung hydati  cysts of 167 
infected cattle slaughtered in at an abattoir located in the southeast of Buenos Aires, Argentina. 168 
Viability was assessed by the methylene blue exclusion test (Elissondo et al., 2007). 169 
 170 
2.8.2. ABZ formulations 171 
 Suspensions were prepared in 100 ml of purified water with the required amount of 172 
suspending agent (CMC) and kept overnight for proper hydration. This solution was used as vehicle 173 
in the preparation of the suspensions. An accurately w ighed quantity of ABZ was distributed in the 174 
vehicle, and Tween 80® was added and mixed gently for 30 min. The ABZ suspen ion (0.29 mg/g) 175 
was vigorously shaken before its intragastric administration to mice. The ABZ-LNCs were prepared 176 















2.8.3. Chemoprophylactic efficacy study 178 
Twenty-four hours after the infection, CF-1 mice were allocated into four experimental 179 
groups (10 animals/group) and treated as follows: a) Control group, animals receiving distilled water 180 
as placebo; b) Control LNCs group, animals receiving blank LNCs; c) ABZ suspension treated 181 
group; d) ABZ-LNCs treated group. The treatment was performed daily for 30 days by intragastric 182 
administration (0.55 ml/animal) at a dose rate of 5 mg/kg. Six months after infection, mice were 183 
euthanized, and necropsy was carried out immediately th reafter. 184 
 185 
2.8.4. Determination of parasite weight and efficacy rate of treatments 186 
At necropsy, the peritoneal cavity was opened, and the cysts were carefully removed. With 187 
The weight of the cysts collected from each individual animal was being recorded using an analytical 188 
scale. The efficacy of treatments, based on the weight of the cysts from infected mice, was calculated 189 
using the following formula: (mean cysts weight of c ntrol group - mean cysts weight of treated 190 
group)/ (mean cysts weight of control group) x 100.  191 
 192 
2.8.5. Morphological study 193 
Samples of cysts recovered from each mouse were proc ssed by SEM as described elsewhere 194 
(Elissondo et al., 2007). 195 
 196 
Statistical analysis 197 
Cysts weights (mean ± SD) were compared by means of the Kruskal–Wallis (non parametric 198 
ANOVA) test followed by Dunn’s multiple comparison test. with a value of P<0.05 was being 199 
considered to be statistically significant. The stati ical analysis was performed using the Instat 3.0 200 
















3. RESULTS  203 
3.1. Development and formulation set up  204 
The first goal in the formulation process was to find out the most convenient core material 205 
able to solubilise a sufficient amount of ABZ. As this drug is sparingly soluble in water and in the 206 
most common organic solvents (Torrado et al., 1996). Preliminarily, The solubility of ABZ in HCl 207 
0.1 M and further encapsulation into the oily inner phase were evaluated since this strategy was 208 
reported as being successful for another hydrophobic drug (Roger et al., 2011). However, in our 209 
study this case, drug loading and EE% were low and were considered not unacceptable for further 210 
applications. Alternatively, ABZ could be solubilised in Thus, co-surfactants and oils were tested but 211 
added to the preparation. Results of this study showed that among the oils and co-surfactants tested 212 
only OA and Transcutol HP® were able to solubilise ABZ.  213 
It is important to highlight that the thermodynamic stability of LNCs is strongly dependent on 214 
the nature of the lipid material utilised as the core. Therefore, the next step was to we evaluated th 215 
combination of the lipids such as Labrafac® or Captex® 8000 and the co-surfactants OA and 216 
Transcutol HP®. Regarding the latter co-surfactant, last one, as only a small quantity of this excipient 217 
(≤0.10 g/g lipid) combined with Labrafac® allowed the production of stable LNCs formulation 218 
consequently, this excipient was discarded. In the case of OA, the maximal amount which leads to 219 
LNCs suspension with acceptable physical properties wa  estimated in 0.25 g/g lipid. Next, in order 220 
to evaluate the efficiency of this  material as an ABZ solubiliser, three batches of LNCs (A, B, and 221 
C; n=3) were manufactured using Labrafac®, Captex® 8000 and a mixture Labrafac®/Captex® 8000 222 
(50/50) respectively as the lipid core and then mixing each one was mixed with OA. Their physical 223 
properties were determined and are listed in Table 1. A blank LNCs suspension using Captex®8000 224 
and OA as the lipid core was included as a reference. 225 















We obtained A monodisperse suspension (PI < 0.2) was obtained with a mean particle size 227 
ranging from 47-56 nm and with a negative zeta potential in all batches. Nevertheless, only in Captex 228 
8000® formulations the   EE% of ABZ was higher than 90% only in Captex 8000® formulations 229 
(batch B, table 1). Moreover, as these physical-chemical features were stable for at least for 1 month; 230 
consequently, the composition of batch B was selectd for further studies. 231 
 232 
3.2. Morphology of ABZ-LNCs 233 
SEM was used to characterise the morphology of the optimised nanoparticles. According to 234 
In Fig. 1.a and 1.b, the observed diameter slightly differed from the values of the DLS 235 
determinations since the LNCs flattened during the drying stage of the in sample preparation, This 236 
observation whichseems to be frequently occur in the study of LNCs by means of this technique 237 
(Lamprecht et al., 2004). The SEM images in Fig. 1.b also showed reveal the homogeneity of the 238 
LNCs, although a few large particles of higher size can be observed.  239 
[Figures 1.a and 1.b] 240 
3.3. Storage stability 241 
Particle stability of particles was assessed for 2 months by storing three batches of the 242 
obtained suspensions at 4-8 ºC. As shown in Table 2, the ABZ loaded in LNCs were physically 243 
stable for at least for 2 months and with no significant changes in mean particle size and or ZP were 244 
being observed. For all formulations, the PI was <0.2, which demonstrates the monodispersity of the 245 
preparations and the with the EE% of ABZ was being higher than 90%. The drug payload (~0.29 246 
mg/g) remained constant and there were no significat differences between the evaluated batches 247 
(P<0.05). 248 
[Table 2] 249 















In view of an oral administration of this formulation,  Considering that this formulation has to 251 
be administered orally, in vitro stability studies in on different simulated gastrointestinal fluids were 252 
first performed. In the gastric medium, which was characterized by a pH of 1.2 and the presence of a 253 
digestive protease (pepsin), a release of about 7% of the initial amount of encapsulated ABZ was 254 
measured after 3 h (Fig. 2). Then, the stability of ABZ-LNCs was assayed in simulated intestinal 255 
fluid media. As it was seen occurred before, ABZ remained encapsulated in the LNCs after 3 h of 256 
incubation (with less than 10% was being released). Also, the size and PI of the nanocarriers were 257 
monitored after incubation in these media (Fig. 3.a and 3.b). The slightly increase in size observed 258 
for the nanocapsules in the first medium was attribu ed to the presence of pepsin, since the system 259 
maintained its particle size in the absence of enzymes (data no shown). Regarding the incubation in 260 
simulated intestinal fluids, it is important to point out that the inclusion of pancreatin, as 261 
recommended by different pharmacopoeias, may have an unpredictable effect over on the lipid 262 
matrix of LNCs since as it is constituted by several nzymes such as amylase, lipase and protease 263 
which present diverse functions and catalytic sites (Prego et al., 2006). Nevertheless, because no 264 
further degradation was observed, and it seems that the chemical composition of these nanocapsules 265 
contributed to the stability of the systems in these this medium. We hypothesize that the shell 266 
composed of the association of free PEG and HS-PEG (Kolliphor® HS-15) in their its outer structure 267 
attached to the oily core improved the stability of the nanosuspension, which otherwise aggregated 268 
massively upon dilution in the incubation medium. 269 
[Figure 2, 3.a and 3.b] 270 
3.5. Chemoprophylactic efficacy study 271 
All the infected mice (10/10) from the control groups and ABZ-treated group developed 272 
hydatidic cysts in the abdominal cavity, whereas in 4 out of the 10 ABZ-LNCs treated mice the 273 
infection did not progress in 4 out of the 10 ABZ-LNCs treated mice. A deleterious drug effect on E. 274 















observed in some animals of the ABZ-LNCs treated groups. The differences in cyst weight among 276 
experimental groups, showing the intragroup variability, are presented in Fig. 4. There was were no 277 
statistically significant differences (P>0.05) betwen the mean cysts weights of the control groups 278 
(distilled water =4.38±3.39 g; blank LNCs = 4.22±2.51 g). On the other hand, significant differences 279 
(P<0.005) were observed in the weight of the cysts recovered from untreated mice compared to that 280 
obtained from ABZ suspension (1.27±0.60 g) and ABZ-LNCs (0.25±0.24 g) treatments. 281 
Interestingly, mice receiving ABZ-LNCs exhibited a higher reduction (P<0.05) in the weight of the 282 
cysts compared to ABZ suspension treated mice.  283 
[Figure 4] 284 
Fig. 5 shows the ultrastructural appearance of the germinal layer after an SEM analysis of 285 
cysts recovered from infected mice. All cysts in the samples removed from control mice appeared 286 
turgid, showing no observable collapse of the germinal layer and no change in ultrastructure was 287 
detected. In contrast, all the cysts developed in mice treated with ABZ-LNCs or ABZ suspension 288 
revealed changes in the germinal layer. A with a reduc d number of germinal cells were being 289 
detected in cysts recovered from the ABZ suspension-treated group (Fig. 5.b). The damage extension 290 
appeared to be greater after ABZ-LNCs. The germinal layer was extensively distorted, where only 291 
debris of cells treatment, as only cell debris could be observed (Fig. 5.c).  292 
 293 
[Figure 5] 294 
DISCUSSION 295 
CE is a neglected disease, especially in developing countries, with which has had an 296 
increasing economic impact due to the need for livelong treatments (Narra et al., 2016). The Radical 297 















accompanied in many cases by chemotherapy. For inoperable cases, ABZ is considered to be a 299 
cornerstone pharmacological treatment.  300 
Nevertheless, Hydrophobicity is an important physicochemical parameter of this drugs which 301 
determines the rate and degree of absorption. In the case of ABZ, its slow dissolution rate limits thus 302 
limiting the production of highly potent ABZ formulations (Teggi, 2004). Nanodrug delivery 303 
systems have been widely reviewed for their use in several formulations to To try to improve drug 304 
bioavailability, prolonged drug release and decrease minimize side effects of many drug candidates 305 
(Allam et al., 2017)., nanosized drug delivery systems have been widely reviewed for different 306 
formulations. Regarding this, particle size and size distribution seems to be one two of the most 307 
important characteristics related to their biodistribution properties. Indeed, the key feature is its an 308 
enlarged surface area, which allows improves dispersion in aqueous environments and leads to a 309 
faster saturation in the dissolution layer around the particles with a consequent increase in dissolution 310 
velocity (Murdande et al., 2015). Different strategies have been developed in order to improve ABZ 311 
water solubility and its dissolution rate, such as preparation of a self-microemulsifying drug delivery 312 
system (Mukherjee and Plakogiannis, 2010), its  incorporation into liposomes (Lv et al., 2013; 313 
Panwar et al., 2010) and its complexation with cyclodextrins (García et al., 2014; Pradines et al., 314 
2014). Alternatively In addition, ABZ solubility has been improved by preparing hot-melt extrusion 315 
formulations with polyvinylpyrrolidone (Hengsawas Surasarang et al., 2016; Martinez-Marcos et al., 316 
2016) and solid lipid nanoparticles (Ahmadnia et al., 2013). Although the  However, preparation 317 
methods which included the use of rotatory evaporators and organic solvents, as well as high 318 
quantity/concentrations of  complexing agents are limiting factors in the application of these 319 
formulations.  320 
LNCs are nanocarriers produced by a simple phase temperature inversion process without the 321 
use of organic solvents and are able to entrap many hydrophobic drugs such as ABZ. The structure of 322 















surrounded by a shell composed made of lecithin and polyethylene-glycol chains (Anton and 324 
Saulnier, 2013; Anton et al., 2007; Huynh et al., 2009). In the present study this work, we have fully 325 
characterised the ABZ-LNCs formulations previously described (Pensel et al., 2015). We achieved 326 
and attained the encapsulation of ABZ (EE% ≥90%) in a stable LNCs formulation with a mean 327 
particle size around 50 nm and an acceptable PI which demonstrates the monodispersity of this 328 
preparation.  329 
Concerning the administration of nanoparticles by the oral route, several biopharmaceutical 330 
parameters should be considered in order to obtain a good efficacy/safety ratio. The first barrier to 331 
overcome after oral administration is constituted by the physicochemical environment of the 332 
gastrointestinal tract. It is known that nanoparticles are susceptible to aggregation in media with a 333 
high ionic strength, extreme pH or high enzyme/protein content, and thus, the surface composition of 334 
the nanocarrier plays an important role in its stabili y (Prego et al., 2006). In this study, we 335 
demonstrated the stability of these nanocapsules in both either the gastric and intestinal media. The 336 
positive effect of the Kolliphor® HS-15 coating used, consisted on was in reducing the number of 337 
interactions of particles with the digestive enzymes and this is in accordance agreement with the 338 
PEG stabilizing effects previously reported by Tobı́o et al., 2000. Moreover, the stability study (Fig. 339 
2) also revealed no burst release of ABZ loaded LNCs, so that the drug transport out of the LNCs 340 
would be may have been driven mainly by a diffusion-c trolled mechanism (Roger et al., 2017). In 341 
consequence, ABZ could be was released for a prolonged period of time from these nanocapsules 342 
means implying a longer residence time in systemic cir ulation, which could consequently can 343 
improve the delivery to target tissues.  344 
In a previous work study, we characterized the plasma and cyst drug exposure after the 345 
administration of ABZ loaded LNCs in mice infected with E. granulosus (Pensel et al., 2015). More 346 
enhanced albendazole sulfoxide (ABZSO) concentration pr files were obtained in plasma and cysts 347 















compared to with those observed after oral administrat on of ABZ suspension. Additionally, the 349 
ABZSO concentrations measured in cysts from ABZ-LNCs treated mice were 1.7-fold higher than 350 
those detected in plasma, . The with this capacity of LNCs to increase oral bioavailability of ABZ 351 
could be possibly  being explained in part, by the gastrointestinal stability of the particles reveled 352 
observed in this investigation.  353 
In the present work The chemoprophylactic efficacy of our formulation was evaluated in our 354 
study by . This study simulating a cyst rupture during surgical practice and the concomitant drug 355 
treatment. Indeed, This is the first report of nanoparticles loaded with ABZ which improving the 356 
chemoprophylactic efficacy of the drug in mice infected with E. granulosus. Interestingly, ABZ 357 
loaded in LNCs have produced a greater preventive effect than ABZ alone, since not only this 358 
reduced not only the number of developed cysts, but may also have inhibited the development of 359 
hydatid cysts in mice.  360 
Metacestodes are fluid-filled vesicles that are separated into: (i) an inner germinal layer 361 
representing the living and metabolically active parasite tissue, and (ii) an outer, acellular 362 
compartment known as the laminated layer, which mediat s the direct physical contact with the host 363 
immune and non-immune cells (Shuhua et al., 2002). As it is seen can be observed in figure 5 6, only 364 
cells debris of cells could be observed for was present in ABZ-LNCs treatments with a marked 365 
alteration in the germinal layer with internal tissue extensively distorted, internal tissue, vacuolated 366 
areas and the presence of lamellar bodies. Altogether T e improved in the therapeutic efficacy of 367 
ABZ-LNCs previously demonstrated could be due to the an increased oral bioavailability of ABZ 368 
due to the enhancement of its permeability across the intestine and/or a decrease of the intestinal 369 
metabolism. However, more specific studies should be performed to get more detailed information 370 
on the host-parasite interactions that occur during dru  treatments. 371 















In conclusion, this study reports on the characterisation of a novel carrier based on the 373 
incorporation of an antiparasitic drug into LNCs and describes their potential use as in CE treatment 374 
was reported. These nanocarriers exhibited attractive adequate properties in terms of size, drug 375 
payload and physicochemical stability which make thm an interesting alternative for the oral 376 
delivery of ABZ. In addition, ABZ-LNCs showed reveal d a higher chemoprophylactic efficacy in 377 
comparison to ABZ suspension administered by the oral r ute. Our results complement and reinforce 378 
are in agreement with the clinical efficacy,  and the observed in previous pharmacokinetics studies 379 
reported before in order to elucidate concerning the mechanism of action of this carrier and its 380 
potential use as a drug delivery system for CE treatm nt in humans. 381 
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Fig.1.a.b. SEM micrographs of ABZ-LNCs (from batch B in table 1).  
Fig.2. Encapsulation efficiency (EE%) of ABZ in LNCs following incubation in simulated 
gastric fluid (SGF) and simulated intestinal fluid (SIF) with enzymes (Mean± SD.; n=3). 
Fig.3. Stability determination of ABZ-LNCs following incubation in simulated gastric fluid 
(SGF) and simulated intestinal fluid (SIF) with enzymes (Mean± SD.; n=3).  a) mean 
particle size, b) polydispersity index (PI). 
Fig.4. Box Plot: Chemoprophylactic efficacy study. Mean (±SD) weights (g) of hydatid 
cysts recovered six months post-infection of from mice from of control groups (water and 
blank LNCs) and treated groups (ABZ-LNCs and ABZ suspension). Treatments were given 
at of 5 mg/kg, every 24 h over for 30 days following fection. The different letters indicate 
statistically significant differences (P<0.05) betwen experimental groups. 
Fig.5. Representative SEM images of hydatid cysts recovered from infected mice during 
the chemoprophylactic efficacy study. a) Cysts from unmedicated animals (gl: germinal 
layer; ×800). b) Cysts recovered from mice treated with ABZ-suspension (5 mg/kg). 
Alteration of the germinal layer (gl) can be appreciated, where observed with only a few 
cells exhibiting an intact morphology (×800). c) Cysts recovered from mice treated with 
ABZ-LNCs (5mg/kg). The germinal layer is altered and with only cell debris of cells can be 













Table 1. Physical-chemical characterisation of different oilcore ABZ-LNCs formulations. 
(Mean± SD.; n=3; PI= polydispersity index).  
 
FORMULATIONS  
 A* B* C* Blank LNCs** 
Size (nm) 56.2±0.2 47.9±1.1 54.2±0.9 49.56±0.74 
PI 0.08 0.08 0.09 0.07 
Zeta potential (mV) -16±2 -18±3 -17±3 -17±2.4 
Encapsulation 
efficiency (%) 
77±2 97.5±1.8 75±4 
- 
Loading (mg/g) 0.22±0.01 0.28±0.002 0.21±0.003 - 
*Lipid matrix: A) Labrafac® + OA; B) Captex®8000 +OA  C) Labrafac®/Captex®8000 (50/50) + OA. 















Table 2. Storage stability. Characterization in terms of size, zeta potential (ZP), encapsulation 
efficiency (EE%) and drug payload of LNCs containing ABZ after 60 days at 4-8 ºC. (Mean ± 





Size (nm) PI ZP (mV) 
0 days 97.5±1.9 0.28±0.05 46.1±1.2 0.08 -14.8±1.8 




































































































• Optimised ABZ-LNCs were obtained through the phase inversion method  
• ABZ-LNCs with a EE >90%) were stable for at least 2 months  
• ABZ remained encapsulated in LNCs after its incubation in simulated biological 
fluids 
• ABZ-LNCs showed a greater chemoprophylactic efficacy than ABZ suspension  
• ABZ-LNCs could be a promising strategy for in the cystic echinococcosis 
treatment 
 
